OncoSignal

Oncogenic pathway identification    

Groundbreaking molecular phenotyping

Revealing tumor-driving mechanisms


OncoSignal assesses the activity of cell signal transduction pathways which drive tumor growth.

mRNA levels regulated by the pathway transcription factor are measured and translated into a quantitative pathway activity score.

 

OncoSignal pathway analysis can be used to reveal aberrant activity of signaling pathways in tumor cells enabling applications for drug response monitoring*, stratification for clinical trials and for cancer research.

*For Research Use Only – not for use in diagnostic procedures.

    OncoSignal pathway analysis

    Signaling pathway activity

    Signaling pathway activity
    *For Research Use Only – not for use in diagnostic procedures.

    How does it work?

    Please view the OncoSignal video to discover the unique features of our solution.
    Philips OncoSignal: Molecular Pathway Dx
    Play

    Products & Services

    OncoSignal service testing        

    • Full service: tissue/RNA-in, result-out
    • ISO13485 compliant
    • ER, AR, PI3K, MAPK, Hedgehog, TGFβ, Notch pathways
    • RNA quality check on each sample
    • Compatible for FFPE, FF and extracted RNA samples

    OncoSignal analysis kit

    • qPCR-based method allowing in-house testing using standard lab equipment
    • Access to Philips software portal for data analysis and generation of the pathway activity report
    • ER, AR, PI3K, MAPK pathways
    • Compatible for FFPE samples

    OncoSignal data analysis

    • Analysis of microarray and RNA-Seq data (generated according to specific requirements)
    • ER, AR, PI3K, MAPK, Hedgehog, TGFβ, Notch, Wnt pathways
    • Data quality checks included
    OncoSignal is available for Research Use Only – not for use in diagnostic procedures.

    Pathway Activity Report

     

    The quantitative pathway activity scores on a 0 to 100 scale (CI = 95%) are presented in the OncoSignal pathway activity report for the pathways requested.

    Pathway activity report

    Applications

    OncoSignal pathway activity analysis can be used for:

    • Molecular phenotypic characterization
    • Model selection for optimal study design
    • Determination of drug-pathway interaction
    • Predicting and monitoring drug response*
    • Patient stratification for clinical trials
     

    Tests are conducted using RNA extracted from fresh frozen (FF) or formalin-fixed paraffin embedded (FFPE) tissue samples, cell cultures or PDX models. For examples on the use of OncoSignal, please request the OncoSignal application note via oncosignal@philips.com.

     

    *For Research Use Only – not for use in diagnostic procedures.

    Upcoming events

    OncoSignal at events 2019
    AACR-NCI-EORTC in Boston, USA
       October 26-30
           Booth #1507
    AMP in Baltimore, USA
    November 7-9
    Booth #2537
    SABCS in San Antonio, USA

    December 10-14

    Booth #806

    OncoSignal at events 2020
    EBCSS in Edinburgh, Scotland
       February 29
           Booth #tbd
    T-ALL in Utrecht, Netherlands
    March 20-22
    Booth #tbd
    AACR in San Diego, USA

    April 24-29

    Booth #1717

    EACR in Turin, Italy

    June 17-20

    Booth #D7

    Recent publications

    • Androgen receptor pathway activity and the ratio between androgen and estrogen receptor pathway activity in breast cancer subtypes, Poster, SABCS 2019
    • The MAPK pathway is variably active across breast cancer subtypes, and increased activity may be associated with hormonal therapy resistance, Poster, SABCS 2019
    • Signal transduction pathway activity in normal fallopian tube epithelium and high-grade serous carcinoma, Poster, ESGO 2019
    • Measuring functional PI3K and NFkB pathway activity to distinguish between short-term and long-term disease-free survivors of high grade serous ovarian cancer, Poster, ESGO 2019
    • Quantitative measurements of functional activity of the TGF&[beta] and MAPK-AP1 pathways in colon cancer provides information on their role in cancer development and metastasis, Poster, ANE 2019
    • Fulvestrant resistance in an MCF-7 model for breast cancer is associated with complete loss of ER pathway activity and gain of MAPK-AP1 pathway activity, Poster, ANE 2019
    • Measurement of decrease in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival in ER positive breast cancer patients, Poster, ESMO 2019
    For copies of one of the above mentioned publications, please email us at oncosignal@philips.com.

    Publications

    For copies of one of the above and below mentioned publications, please email us at oncosignal@philips.com.
    • Heterogeneity in Signaling Pathway Activity within Primary Breast Cancer and between Primary and Metastases, Poster, ASCO 2019
    • ER pathway activity score as a predictive biomarker to improve stratification for neo-adjuvant endocrine therapy, Poster, ESMO Breast Congress 2019
    • Quantitative measurement of multiple signal transduction pathway activities in cell and tissue culture, including cancer, fibroblasts, and immune cell types: a new way forward to standardization of cell culture experiments, Poster, AACR 2019
    • Breast cancer induces a tolerogenic state of healthy activated CD4+ T-cells, characterized by reduced PI3K, NFκB, JAK-STAT, Notch, and increased TGFβ pathway activity, Poster, AACR 2019
    • Elucidating the role of functional signal trasnduction pathway activity in sensitivity and response of triple negative breast cancer PDxs to PI3K inhibition, Poster, SABCS 2018
    • Does Hormone Expression by IHC predict ER Pathway Activity? An Analysis in A Metastatic Breast Cancer Patient Cohort. Poster, SABCS 2018
    • Assays for measurement of functional signal transduction pathway activity in any cell or tissue sample, Poster, Keystone 2018
    • Signal transduction pathway activity before and after neoadjuvant treatment in esophageal cancer, Poster, ESMO 2018
    • Estrogen receptor pathway activity in endometrial carcinomas and its relation to tumor grade and disease related mortality, Poster, ESMO 2018
    • Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma, Poster, ESMO 2018
    • Assessment of functional signal transduction pathway activity in patient-derived tumor xenografts to predict and evaluate therapy response, Poster, ENA 2018
    • Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma, Poster, EACR 2018
    • Robust measurement of signal transduction pathway activity in cancer using RNA sequencing on cells and FFPE tissue, Poster, AMPEu 2018
    • Measuring functional signal transduction pathway activity on breast cancer tissue samples to determine intra-tumor heterogeneity and heterogeneity between primary and metastatic tumors, Poster, AACR 2018
    • Determination of signal transduction pathway activity in patient-derived xenograft models in comparison with clinical patient tumor samples for a variety of human cancer types, Poster, AACR 2018
    • Measuring functional PI3K pathway activity in cancer tissue using FOXO target gene expression in a knowledge-based computational model, Poster, SABCS 2017
    • Complete sequence-based pathway analysis by differential on-chip DNA and RNA extraction from a single cell, Nature Scientific Reports, 2017
    • Assessing functional androgen receptor (AR) pathway activity using a computational model, Poster, ESMO 2017
    • Oncogenic signal transduction pathway activity in glioblastoma and relation to therapy response, Poster, EACR Cancer Genomics 2017
    • Analysis of active oncogenic signal transduction pathways in HGS ovarian cancer HH pathway activity associated with platin resistance, Poster, AMP 2017
    • Elucidating pediatric brain tumor pathophysiology by assessing signal transduction pathway activation, Poster, AACR 2017
    • Predicting first line tamoxifen response of recurrent ER+ breast cancer patients based on transcriptional activity of signaling pathways, Poster, AACR 2016
    • Prognosis within different breast cancer subtypes using functional activity of signaling pathways, Poster, AACR 2015
    • Assessing functional ER pathway activity using a computational pathway model, Poster, EACR 2014
    • Selection of Personalized Patient Therapy through the Use of Knowledge-Based Computational Models That Identify Tumor-Driving Signal Transduction Pathways, Cancer Research, 2014
    • Knowledge-based computational models, Oncotarget, 2014
    • Identifying tumor driving signaling pathways using computational pathway models, Poster, AACR 2013
    • Personalized Cancer Treatment Selection using Computational Signaling Pathway Models, Poster, SABCS 2011

    Clinical Advisory Board

    • Fabrice André, MD, PhD, Gustave Roussy, Villejuif (France)
    • Carlos L. Arteaga, MD, UT Southwestern Medical Center, Dallas (USA)
    • Jean-Yves Blay, MD, PhD, Centre Léon Bérard, Lyon (France)
    • Fabien Calvo, MD, PhD, University of Paris Denis Diderot Medical School, Paris (France)
    • Carla van Herpen, MD, PhD, Radboud University Medical Center, Nijmegen (The Netherlands)
    • Hatim Husain, MD, University of California, San Diego (USA)
    • Cynthia Ma, MD, PhD, Washington University Medical School, St. Louis (USA)
    • Christophe Massard, MD, PhD, Gustave Roussy, Villejuif (France)
    • Hans Prenen, MD, PhD, Antwerp University Hospital, Edegem (Belgium)
    • Dirk de Ruysscher, MD, PhD, Maastro, Maastricht University Medical Center, Maastricht (The Netherlands)
    • Cristina Saura, MD, PhD, Vall d'Hebron University Hospital, Barcelona (Spain)
    • Karen Willard-Gallo, PhD, Institut Jules Bordet, Brussels (Belgium)

    EIT Health

    Functional signaling Pathway ACtivity complementing DNA Mutation ANalysis for precision medicine (PACMAN)

    PACMAN will test how well the OncoSignal solution increases the effectiveness of new, personalised cancer therapy. Significant progress has been made with targeted drugs that block tumour-driving molecular pathways, but it is still difficult to predict how patients will respond. OncoSignal was designed to improve selection of optimal personalised therapy for individual patients.

     

    Impact

     

    OncoSignal will contribute to disruption of cancer care by moving from treatment based on cancer type to tumour biology. Assessment of the functional molecular phenotype will provide improved therapy response prediction compared to DNA genotyping analysis alone. The project promises to:

     

    • improve clinical outcomes, especially for hard-to-treat cancers;
    • reduce unnecessary side effects from ineffective therapies;
    • save costs due to more effective (personalised) therapies.

     

    For more information, please visit www.eithealth.eu/pacman.

    EIT Health logo

    Kontaktinformasjon

    * Dette feltet er obligatorisk
    *
    *
    *
    *
    *
    *
    *
    *
    *
    Ved å spesifisere hvorfor du kontakter oss vil vi kunne yte en bedre service.
    *
    *